Zavante Overview
- Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
8
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$97.5M
Zavante General Information
Description
Developer of novel medicines for the treatment of diseases that affect patients in the hospital setting. The company's lead product candidate is an investigational, first-in-class injectable antibiotic under development to combat serious, life-threatening infections, including those due to multi-drug resistant (MDR) Gram-negative and Gram-positive bacteria.
Contact Information
Primary Office
- 11750 Sorrento Valley Road
- Suite 250
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Zavante Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 24-Jul-2018 | $97.5M | 000.00 | 000.00 | Completed | Generating Revenue |
| 2. Debt - General | 01-Sep-2016 | 0000 | 000.00 | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 04-Apr-2016 | $45.7M | $45.7M | 000.00 | Completed | Generating Revenue |
Zavante Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Zavante Patents
Zavante Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018277757-A1 | Methods of identifying novel dosing regimens | Pending | 30-May-2017 | 0000000000 | |
| US-11541064-B2 | Methods of identifying dosing regimens | Active | 30-May-2017 | 0000000000 | 0 |
| US-20200253992-A1 | Methods of identifying novel dosing regimens | Active | 30-May-2017 | 0000000000 | |
| JP-2022137084-A | Method for identifying novel dosing regimen | Pending | 09-Jan-2017 | 000000000 | |
| US-11129840-B2 | Methods for identifying novel dosing regimens | Active | 09-Jan-2017 | A61P31/04 |
Zavante Executive Team (13)
Zavante Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Cam Garner | Self | Co-Founder & Chairman | 000 0000 |
| Theodore Schroeder | Self | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
Zavante Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Zavante Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Frazier Healthcare Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Global Source Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Longitude Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Mesa Verde Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |